Loading...
XKRX
290650
Market cap493mUSD
Jun 12, Last price  
30,100.00KRW
Name

L&C Bio Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
4.84
P/S
9.47
EPS
6,218.42
Div Yield, %
—
Shrs. gr., 5y
0.64%
Rev. gr., 5y
19.85%
Revenues
72.09b
+4.68%
8,999,068,63011,821,737,96017,900,842,82021,240,893,56029,151,665,34032,972,771,33045,677,013,79052,572,492,15068,869,546,32072,093,323,400
Net income
141.06b
+191.69%
1,202,060,7501,981,143,8903,753,072,9505,207,676,9107,250,030,33010,813,093,57013,814,433,3004,544,175,31048,361,014,774141,064,260,540
CFO
-8.57b
L-29.39%
-1,327,717,960-185,353,5703,818,116,8103,845,774,8206,430,855,6207,419,054,67010,906,636,010-6,075,796,000-12,132,875,370-8,566,586,940
Dividend
Dec 27, 2023100 KRW/sh

Profile

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.
URL
http://www.lncbio.co.kr/
IPO date
Nov 01, 2018
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
72,093,323
4.68%
68,869,546
31.00%
52,572,492
15.10%
Cost of revenue
59,440,060
54,464,918
37,196,504
Unusual Expense (Income)
NOPBT
12,653,264
14,404,628
15,375,988
NOPBT Margin
17.55%
20.92%
29.25%
Operating Taxes
(5,444,646)
14,406,644
(1,128,659)
Tax Rate
100.01%
NOPAT
18,097,909
(2,016)
16,504,647
Net income
141,064,261
191.69%
48,361,015
964.24%
4,544,175
-67.11%
Dividends
(2,268,489)
(1,114,923)
(1,114,923)
Dividend yield
0.41%
0.16%
0.21%
Proceeds from repurchase of equity
(840,000)
BB yield
0.12%
Debt
Debt current
99,862,626
80,716,755
10,641,266
Long-term debt
29,270,090
3,689,939
73,008,551
Deferred revenue
10
1,270,939
Other long-term liabilities
2,066,568
2,118,761
(40)
Net debt
80,345,050
(23,616,890)
(5,253,024)
Cash flow
Cash from operating activities
(8,566,587)
(12,132,875)
(6,075,796)
CAPEX
(4,715,476)
(24,502,960)
(37,703,137)
Cash from investing activities
(21,946,170)
24,634,288
(83,632,541)
Cash from financing activities
33,830,328
(4,155,265)
78,927,600
FCF
7,830,166
(42,135,080)
(39,402,647)
Balance
Cash
24,137,343
59,192,647
12,316,496
Long term investments
24,650,322
48,830,938
76,586,345
Excess cash
45,183,000
104,580,107
86,274,216
Stockholders' equity
243,957,890
114,443,754
107,028,373
Invested Capital
375,509,429
136,528,368
94,134,214
ROIC
7.07%
25.35%
ROCE
3.01%
5.97%
8.06%
EV
Common stock shares outstanding
22,682
24,722
22,685
Price
24,100.00
-16.90%
29,000.00
25.54%
23,100.00
-36.89%
Market cap
546,645,358
-23.75%
716,945,018
36.82%
524,020,982
-35.79%
EV
637,362,633
710,536,548
528,637,111
EBITDA
19,407,416
20,059,040
19,883,740
EV/EBITDA
32.84
35.42
26.59
Interest
3,221,085
6,191,078
3,076,147
Interest/NOPBT
25.46%
42.98%
20.01%